Intravitreal anti-VEGF bevacizumab (Avastin) for external beam-related radiation retinopathy

European Journal of Ophthalmology

Volumn 21, Issue 4, 2011, Pages 446-451

  Finger, Paul T ^a,c   Mukkamala, Sri Krishna ^b  

^a NEW YORK EYE CANCER CENTER   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti VEGF; Avastin; Photon; Proton; Radiation; Retinopathy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADENOCARCINOMA; ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; EYE DISEASE; FEMALE; HUMAN; INTRAOCULAR LYMPHOMA; LACRIMAL GLAND ADENOID CYSTIC CARCINOMA; LACRIMAL GLAND DISEASE; LYMPHOMA; MALE; MARGINAL ZONE LYMPHOMA; MAXILLA TUMOR; OPTIC NERVE DISEASE; PRIORITY JOURNAL; RADIATION INJURY; RETINA MACULA HEMORRHAGE; RETINA MACULOPATHY; RETINA VEIN OCCLUSION; RETINOPATHY; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VITRECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EYE NEOPLASMS; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RETINA; RETINAL DISEASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79957796328     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2011.6213     Document Type: Article

References (26)

1. Gupta A, Dhawahir-Scala F, Smith A, Young L, Charles S. Radiation retinopathy: case report and review. BMC Ophthalmol 2007; 7: 6.
2. Finger PT, Chin KJ, Yu GP. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol 2010; 149: 608-15.
3. Finger PT, Chin KJ, Duvall G. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology 2009; 116: 790-6.
4. Finger PT. Radiation therapy for orbital tumors: concepts, current use, and ophthalmic radiation side effects. Surv Ophthalmol 2009; 54: 545-68.
5. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30: 765-73.
6. Takeda A, Shigematsu N, Suzuki S, et al. Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity. Int J Radiat Oncol Biol Phys 1999; 44: 599-605.
7. Gardiner TA, Amoaku WM, Archer DB. The combined effect of diabetes and ionising radiation on the retinal vasculature of the rat. Curr Eye Res 1993; 12: 1009-14.
8. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol 1997; 42: 215-32.
9. Gall N, Leiba H, Handzel R, Pe'er J. Severe radiation retinopathy and optic neuropathy after brachytherapy for choroidal melanoma, treated by hyperbaric oxygen. Eye 2007; 21: 1010-2.
10. Borruat FX, Schatz NJ, Glaser JS, Feun LG, Matos L. Visual recovery from radiation-induced optic neuropathy: the role of hyperbaric oxygen therapy. J Clin Neuroophthalmol 1993; 13: 98-101.
11. Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2005; 89: 730-8.
12. Chaudhuri PR, Austin DJ, Rosenthal AR. Treatment of radiation retinopathy. Br J Ophthalmol 1981; 65: 623-5.
13. Kocak N, Saatci AO, Arikan G, Bajin FM. Combination of photodynamic therapy, intravitreal triamcinolone injection, and standard laser photocoagulation in radiation retinopathy: a case report. Ann Ophthalmol 2006; 38: 243-7.
14. Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol 2007; 125: 751-6.
15. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 2008; 70: 974-7.
16. Finger PT, Chin KJ. Intravitreous ranibizumab (Lucentis) for radiation maculopathy. Arch Ophthalmol 2010; 128: 249-52.
17. Arriola-Villalobos P, Donate-Lopez J, Calvo-Gonzalez C, Reche-Frutos J, Alejandre-Alba N, Diaz-Valle D. Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization. Acta Ophthalmol 2008; 86: 115-6.
18. Loukianou E, Brouzas D, Georgopoulou E, Koutsandrea C, Apostolopoulos M. Intravitreal bevacizumab for macular edema due to proton beam radiotherapy: favorable results shown after eighteen months follow-up. Ther Clin Risk Manag 2010; 6: 249-52.
19. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation optic neuropathy after megavoltage externalbeam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30: 755-63.
20. Mason JO III, Albert MA Jr, Persaud TO, Vail RS. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina 2007; 27: 903-7.
21. Gupta A, Muecke JS. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina 2008; 28: 964-8.
22. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009; 23: 2187-93.
23. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008; 28: 564-7.
24. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye 2007; 21: 1541.
25. Finger PT. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol 2007; 143: 335-8.
26. Finger PT, Chin KJ. Anti vascular endothelial growth factor (anti-VEGF) Avastin for radiation optic neuropathy: Secondary to plaque radiation therapy. J Radiat Oncol Biol Phys 2011, In Press.